Open communication helps ulcerative colitis patients through COVID-19Gastroenterologist Dr Séverine Vermeire explains how lockdowns and communication changes over COVID-19 are taking their toll on ulcerative Share XOpen communication helps ulcerative colitis patients through COVID-19https://pharmaphorum.com/views-analysis-patients/open-communication-helps-ulcerative-colitis-patients-through-covid-19/
Data sets up ulcerative colitis expansion for BMS’ MS drug ZeposiaBristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – Share XData sets up ulcerative colitis expansion for BMS’ MS drug Zeposiahttps://pharmaphorum.com/news/data-sets-up-ulcerative-colitis-expansion-for-bms-ms-drug-zeposia/
Despite biosims, ulcerative colitis drugs still cost too much; ICERNone of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough Share XDespite biosims, ulcerative colitis drugs still cost too much; ICERhttps://pharmaphorum.com/news/despite-biosims-ulcerative-colitis-drugs-still-cost-too-much-icer/
Analysts question Gilead’s commitment to arthritis drug after FDA setbackThe FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage Share XAnalysts question Gilead’s commitment to arthritis drug after FDA setbackhttps://pharmaphorum.com/news/gilead-could-become/
Roche’s ulcerative colitis drug etrolizumab looks shaky after data roll-outRoche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans Share XRoche’s ulcerative colitis drug etrolizumab looks shaky after data roll-outhttps://pharmaphorum.com/news/roches-ulcerative-colitis-drug-etrolizumab-looks-shaky-after-data-roll-out/
BMS launches COVID-19 delayed MS drug Zeposia in USBristol-Myers Squibb opted not to launch its new multiple sclerosis therapy Zeposia when it got FDA approval in Share XBMS launches COVID-19 delayed MS drug Zeposia in UShttps://pharmaphorum.com/news/bms-launches-covid-19-delayed-ms-drug-zeposia-in-us/
Gilead and Galapagos shares hit as filgotinib disappointsGilead and Galapagos’ late-stage trial of their ulcerative colitis drug filgotinib has hit its target – but shares Share XGilead and Galapagos shares hit as filgotinib disappointshttps://pharmaphorum.com/news/gilead-and-galapagos-shares-hit-as-filgotinib-disappoints/
California’s AMT is latest biotech aiming to go public in pandemic IPO crazeCalifornia’s Applied Molecular Transport has become the latest biotech to go for an IPO during the pandemic, aiming Share XCalifornia’s AMT is latest biotech aiming to go public in pandemic IPO crazehttps://pharmaphorum.com/news/californias-amt/
COVID-19 and vulnerable children: Urging caution while enjoying childhoodHow do you keep a child with a suppressed immune system safe during COVID-19 lockdown? And how do Share XCOVID-19 and vulnerable children: Urging caution while enjoying childhoodhttps://pharmaphorum.com/views-analysis-patients/covid-19-vulnerable-children/